Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

NCT07644559 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT07644559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07644559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
Lead sponsor
Verastem, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 16, 2026
Completion date
December 31, 2028
Enrollment
185 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

g12d mutated kras, pancreatic ductal adenocarcinoma (pdac)